Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis.

This is a Meta-Analysis study (also classified as: Systematic Review).

May 4, 2026

View Full Paper

Ask AI

Bookmark

Share

Key Points

To describe the features, treatments, and outcomes related to tumefactive demyelinating lesions (TDLs).
Followed PRISMA guidelines for systematic review and meta-analysis.
Included biopsy-confirmed cases of TDL greater than 2 cm on magnetic resonance imaging (MRI).
Conducted exploratory subgroup analyses and assessed publication bias.
Identified a high response rate to acute treatment with intravenous methylprednisolone (IVMP).
Noted variability in nomenclature and presentation of TDLs across studies.
Results should be interpreted cautiously due to a small number of contributing studies.

We only have this paper's title and publication details.

Systematic review highlights clinical features and treatment responses in demyelination, indicating variability across cases.

No takes yet. Share an insight, caveat, or question.

Alaskar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share